We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
EA
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Trevi Therapeutics
TRVI
$2.64B
| $2.02M | 0.02% |
+606,227
| New | +$1.8M |
|
477
Perrigo
PRGO
$1.78B
| $1.99M | 0.02% |
75,819
| – | – |
|
|
TECX
478
Tectonic Therapeutic
TECX
$606M
| $1.98M | 0.02% |
+65,448
| New | +$1.2M |
|
479
Relay Therapeutics
RLAY
$4.33B
| $1.96M | 0.02% |
276,904
+3,288
| +1% | +$24.6K |
|
480
Lexicon Pharmaceuticals
LXRX
$1.1B
| $1.9M | 0.02% |
+1,211,924
| New | +$2.16M |
|
|
SLRN
481
DELISTED
ACELYRIN
SLRN
| $1.76M | 0.01% |
357,094
-1,627,716
| -82% | -$8.4M |
|
482
MP Materials
MP
$9.1B
| $1.76M | 0.01% |
+99,512
| New | +$1.35M |
|
483
Trane Technologies
TT
$106B
| $1.72M | 0.01% |
+4,423
| New | +$1.53M |
|
|
TWFG
484
TWFG Inc
TWFG
$378M
| $1.68M | 0.01% |
+62,000
| New | +$1.61M |
|
|
THRD
485
DELISTED
Third Harmonic Bio
THRD
| $1.68M | 0.01% |
+123,923
| New | +$1.54M |
|
486
ImmunityBio
IBRX
$8.1B
| $1.64M | 0.01% |
439,818
+1,975
| +0.5% | +$9.14K |
|
487
SkinHealth Systems
SKIN
$85.7M
| $1.57M | 0.01% |
1,091,000
-1,411,320
| -56% | -$2.31M |
|
488
Protara Therapeutics
TARA
$232M
| $1.56M | 0.01% |
851,567
+751,566
| +752% | +$1.54M |
|
489
Zscaler
ZS
$27.3B
| $1.54M | 0.01% |
9,030
-17,153
| -66% | -$3.13M |
|
|
RGLS
490
DELISTED
Regulus Therapeutics
RGLS
| $1.49M | 0.01% |
948,702
+1,017
| +0.1% | +$1.68K |
|
491
DigitalOcean
DOCN
$14.6B
| $1.49M | 0.01% |
36,865
-55,419
| -60% | -$1.98M |
|
492
SPS Commerce
SPSC
$2.64B
| $1.45M | 0.01% |
+7,475
| New | +$1.47M |
|
493
Alto Neuroscience
ANRO
$1.11B
| $1.43M | 0.01% |
125,000
| – | – |
|
494
Brinker International
EAT
$9.66B
| $1.41M | 0.01% |
18,435
-73,760
| -80% | -$5.08M |
|
|
PSTX
495
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $1.37M | 0.01% |
+478,861
| New | +$1.48M |
|
496
Tyra Biosciences
TYRA
$1.58B
| $1.31M | 0.01% |
55,866
-32,790
| -37% | -$688K |
|
497
AST SpaceMobile
ASTS
$21.5B
| $1.31M | 0.01% |
+50,000
| New | +$1.13M |
|
498
Pliant Therapeutics
PLRX
$65M
| $1.25M | 0.01% |
111,660
+8,037
| +8% | +$101K |
|
|
MASI
499
DELISTED
Masimo
MASI
| $1.24M | 0.01% |
9,300
-176,690
| -95% | -$20.5M |
|
500
HUB Group
HUBG
$2.92B
| $1.23M | 0.01% |
+27,001
| New | +$1.2M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.